The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance).
Erin Van Blarigan
No Relationships to Disclose
Charles S. Fuchs
Consulting or Advisory Role - Agios; Bayer; Dicerna; Entrinsic Health; Five Prime Therapeutics; Genentech/Roche; Gilead Sciences; KEW; Lilly; Merck; Merrimack; Sanofi; Taiho Pharmaceutical
Donna Niedzwiecki
No Relationships to Disclose
Xing Ye
No Relationships to Disclose
Sui Zhang
No Relationships to Disclose
Mingyang Song
No Relationships to Disclose
Leonard Saltz
Consulting or Advisory Role - Abbvie; Lilly; McNeil PPC (I)
Research Funding - Taiho Pharmaceutical
Robert J. Mayer
Honoraria - Taiho Pharmaceutical
Consulting or Advisory Role - CASI Pharmaceuticals
Rex B. Mowat
No Relationships to Disclose
Renaud Whittom
No Relationships to Disclose
Alexander Hantel
Travel, Accommodations, Expenses - Genentech
Al Bowen Benson
Consulting or Advisory Role - Alchemia; Astellas Pharma; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech/Roche; Guardant Health; Guerbet; Helsinn Healthcare; Infinity Pharmaceuticals; IntegraGen; Lexicon; Lilly/ImClone; Merck Serono; Merck/Schering Plough; National Cancer Institute; Novartis; Opsona Therapeutics; Pharmacyclics; Precision Therapeutics; Sanofi; Spectrum Pharmaceuticals; Taiho Pharmaceutical; Vicus Therapeutics
Research Funding - advanced accelerator applications (Inst); Alchemia (Inst); Amgen (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer/Onyx (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Bayer; Boehringer Ingelheim; Boston Biomedical; Dava Oncology; Genentech/Roche; Gilead Sciences; Guardant Health; guerbet; Helsinn Healthcare; Lilly/ImClone; Sanofi; Spectrum Pharmaceuticals; TRM Oncology
Daniel M. Atienza
No Relationships to Disclose
Michael J. Messino
No Relationships to Disclose
Hedy L. Kindler
Consulting or Advisory Role - Aduro Biotech; AstraZeneca; Bayer; Celgene; Genentech/Roche; GlaxoSmithKline; MedImmune; Merck; Plexxikon; Verastem
Research Funding - AB Science; Aduro Biotech; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Incyte; Lilly; MedImmune; Merck; Verastem
Expert Testimony - Aduro Biotech
Alan P. Venook
Honoraria - Gilead Sciences
Consulting or Advisory Role - Gilead Sciences; Merrimack
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Serono (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech; Merck Serono; Merrimack; Roche; Taiho Pharmaceutical
Shuji Ogino
No Relationships to Disclose
Walter C. Willett
No Relationships to Disclose
Edward L. Giovannucci
No Relationships to Disclose
Jeffrey A. Meyerhardt
Research Funding - Biothera (Inst)